Phase 3 study · Biohaven · NCT07642050
Biohaven's phase 3 BHV-1400 study for IgA nephropathy
About 420 adults are planned. Two of every 3 people get BHV-1400 and 1 in 3 gets a placebo, and neither the patient nor the study team knows which.
Biohaven said on October 29, 2026 that it is on track to start this Phase 3 study in the fourth quarter of 2026. The ClinicalTrials.gov listing still shows an estimated start of June 2026. Source: Biohaven third quarter 2026 results, October 29, 2026
Get one email when it opens
We send an email only when the study starts enrolling or adds a US site. Your email is used for nothing else.
Free email alert
Hear when Biohaven's phase 3 BHV-1400 study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your nephrologist.
1. Are you between 18 and 70 years old?
2. Has a kidney biopsy confirmed your IgA nephropathy in the last 10 years?
If you have diabetes, the listing asks for a biopsy within 2 years. If no biopsy report is available, the listing says a biopsy may be done before screening.3. Is your latest urine protein at least 0.75g/g (UPCR), or at least 1g a day on a 24-hour urine test?
Your nephrologist's office can tell you your latest number.4. Is your eGFR, the kidney filtering number on your blood test, 30 or higher?
5. Have you taken an ACE inhibitor or ARB blood pressure medicine at a steady dose for at least 90 days?
Examples are lisinopril and losartan. The listing says people who cannot take these may still be considered.6. Are you on dialysis, or have you had a kidney transplant?
The study team also checks for these, which are easier to go over with your nephrologist:
- IgA nephropathy caused by another condition, such as cirrhosis, celiac disease or HIV
- Another cause of kidney disease, such as diabetic kidney disease
- A fast drop in kidney function, 50% or more in the 3 months before screening
- Nephrotic syndrome in the past 6 months
- Other kidney medicines, such as an SGLT2 inhibitor or sparsentan, which must be at a steady dose for 90 days
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
No US sites are listed yet. Follow the study in step 1 and we'll email you the day sites are added.
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07642050.
Questions people ask about Biohaven's phase 3 BHV-1400 study
Is Biohaven's phase 3 BHV-1400 study enrolling now?
ClinicalTrials.gov lists it as not yet recruiting, as of its last update there on 2026-06-11. Biohaven said on October 29, 2026 that it is on track to start this Phase 3 study in the fourth quarter of 2026. The ClinicalTrials.gov listing still shows an estimated start of June 2026. Follow it on this page to get one email when it opens or adds US sites.
Where are the US sites for Biohaven's phase 3 BHV-1400 study?
No US sites are listed yet. Following the study here sends one email the day US sites are added.
Who can join Biohaven's phase 3 BHV-1400 study?
About 420 adults are planned. The main listed requirements are in the pre-check on this page, starting with: adults 18 to 70 years old. Only the study team decides who can join.
How do I contact the Biohaven's phase 3 BHV-1400 study team?
The listing names this contact: Biohaven clinical trials, 203-404-0410, clinicaltrials@biohavenpharma.com. Each site may also list its own contact on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, Biohaven. This page restates the public listing in plain words, and nothing here is medical advice; talk with your nephrologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07642050, last updated there 2026-06-11. Questions checked against the listing on November 9, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your nephrologist about whether a study is right for you.